As part of the Cancer Molecular Screening and Therapeutics (MoST) Program, the MoST9 study aims to evaluate the activity of the combination of tucatinib and trastuzumab in patients with advanced tumours harbouring HER2 amplification or mutations.
Who can participate in MoST9?
Patients aged 18 years and older with:
- Pathologically confirmed advanced and/or metastatic solid cancer of any histologic type or an earlier diagnosis of a poor prognosis cancer
- Tumours harbouring HER2 amplification or mutations
For more information please contact: email@example.com